Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
BMEA

BMEA - Biomea Fusion, Inc. Stock Price, Fair Value and News

11.21USD-0.29 (-2.52%)Delayed as of 23 May 2024, 02:02 pm ET

Market Summary

BMEA
USD11.21-0.29
Delayedas of 23 May 2024, 02:02 pm
-2.52%

BMEA Stock Price

View Fullscreen

BMEA RSI Chart

BMEA Valuation

Market Cap

413.4M

Price/Earnings (Trailing)

-3.25

Price/Sales (Trailing)

41.76

Price/Free Cashflow

-3.93

BMEA Price/Sales (Trailing)

BMEA Profitability

Return on Equity

-94.05%

Return on Assets

-75.53%

Free Cashflow Yield

-25.42%

BMEA Fundamentals

BMEA Revenue

Revenue (TTM)

9.9M

Rev. Growth (Yr)

103.88%

Rev. Growth (Qtr)

-18.25%

BMEA Earnings

Earnings (TTM)

-127.3M

Earnings Growth (Yr)

-34.46%

Earnings Growth (Qtr)

-11.97%

Breaking Down BMEA Revenue

52 Week Range

11.2143.69
(Low)(High)

Last 7 days

-13.1%

Last 30 days

6.2%

Last 90 days

-28.7%

Trailing 12 Months

-63.0%

How does BMEA drawdown profile look like?

BMEA Financial Health

Current Ratio

5.84

BMEA Investor Care

Shares Dilution (1Y)

1.54%

Diluted EPS (TTM)

-3.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.9M000
20232.8M5.3M7.4M8.9M
2022129.0K309.0K871.0K1.8M
202126.7K50.3K74.0K100.0K
20200003.0K

Tracking the Latest Insider Buys and Sells of Biomea Fusion, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 29, 2023
erdtmann rainer m
gifted
-
-
-21,000
president and coo
Dec 29, 2023
erdtmann rainer m
gifted
-
-
3,000
president and coo
Dec 29, 2023
erdtmann rainer m
gifted
-
-
6,000
president and coo
Nov 30, 2023
valle franco
acquired
5,087
3.7825
1,345
chief financial officer
Jun 01, 2023
a2a pharmaceuticals, inc.
sold
-1,728,160
34.5633
-50,000
-
May 31, 2023
a2a pharmaceuticals, inc.
sold
-2,535,750
33.81
-75,000
-
May 31, 2023
valle franco
acquired
16,162
3.7825
4,273
chief financial officer
May 12, 2023
a2a pharmaceuticals, inc.
sold
-846,000
33.84
-25,000
-
May 09, 2023
a2a pharmaceuticals, inc.
sold
-5,175,720
34.5048
-150,000
-
May 08, 2023
a2a pharmaceuticals, inc.
sold
-3,399,310
33.9931
-100,000
-

1–10 of 42

Which funds bought or sold BMEA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.11
42,587
102,587
0.01%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-4.36
-5,300
341,757
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-88.56
-4,057,200
541,459
-%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
reduced
-75.84
-1,507,870
499,345
-%
May 15, 2024
Engineers Gate Manager LP
sold off
-100
-623,634
-
-%
May 15, 2024
BAKER BROS. ADVISORS LP
unchanged
-
906,849
31,528,800
0.40%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-61.69
-1,372,280
893,816
-%
May 15, 2024
Squarepoint Ops LLC
sold off
-100
-1,602,670
-
-%
May 15, 2024
MARSHALL WACE, LLP
reduced
-82.23
-2,841,660
636,452
-%
May 15, 2024
Bayesian Capital Management, LP
new
-
404,263
404,263
0.04%

1–10 of 36

Are Funds Buying or Selling BMEA?

Are funds buying BMEA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BMEA
No. of Funds

Unveiling Biomea Fusion, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
state street corp
12.50%
4,485,615
SC 13G
Feb 14, 2024
baker bros. advisors lp
5.9%
2,108,949
SC 13G/A
Feb 12, 2024
butler thomas andrew
10.4%
3,802,482
SC 13G/A
Feb 12, 2024
erdtmann rainer m
7.8%
2,820,900
SC 13G/A
Feb 12, 2024
janus henderson group plc
4.8%
1,718,245
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
laurion capital management lp
7.66%
2,736,367
SC 13G
Jan 29, 2024
blackrock inc.
6.0%
2,156,342
SC 13G
May 10, 2023
fmr llc
-
0
SC 13G
Apr 03, 2023
cormorant global healthcare master fund, lp
5.08%
1,795,928
SC 13D/A

Recent SEC filings of Biomea Fusion, Inc.

View All Filings
Date Filed Form Type Document
May 02, 2024
8-K
Current Report
May 02, 2024
10-Q
Quarterly Report
Apr 26, 2024
DEF 14A
DEF 14A
Apr 26, 2024
ARS
ARS
Apr 10, 2024
SC 13G
Major Ownership Report
Apr 01, 2024
8-K
Current Report
Apr 01, 2024
8-K
Current Report
Mar 28, 2024
10-K
Annual Report
Mar 07, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Biomea Fusion, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

Biomea Fusion, Inc. News

Latest updates
Yahoo Canada Shine On18 May 202410:35 pm
Defense World06 May 202407:00 am
Seeking Alpha02 Apr 202407:00 am
Markets Insider5 months ago

Biomea Fusion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Revenue-18.2%1,9982,4442,6902,76698096259421634.0027.0032.0036.005.001.002.002.00
Operating Expenses10.0%41,05937,32831,11927,65730,03126,27623,48417,47416,40014,73712,6388,4355,8573,4991,135295
  S&GA Expenses-100.0%-6,4625,7725,7195,6365,7375,2424,8925,0503,6494,7523,2112,0591,16734679.00
  R&D Expenses9.4%33,77630,86625,34721,93824,39520,53918,24212,58211,35011,0887,8865,2243,7982,332789216
Net Income-12.0%-39,061-34,884-28,429-24,891-29,051-25,314-22,890-17,258-16,366-14,710-12,606-8,399-5,852-3,498-1,135-293
Net Income Margin2.6%-12.86*-13.20*-14.56*-19.27*-34.34*-45.31*-81.77*-197.22*-403.73*-415.67*-410.20*-375.18*-404.17*-1.77--
Free Cashflow-40.4%-32,065-22,845-23,938-26,229-26,950-20,913-16,745-15,700-10,089-16,192-11,028-7,247-4,142---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets-15.7%16820022524911312914516217518619921060.0063.00
  Current Assets-17.6%14817920322689.0011813915416717719120148.0062.00
    Cash Equivalents-17.9%14517719922386.0011213214815614615716619.0062.00
  Net PPE-6.8%5.005.006.006.006.006.003.003.003.003.003.001.000.000.00
Liabilities8.1%33.0031.0025.0024.0030.0021.0014.0011.0010.007.008.008.004.002.00
  Current Liabilities10.5%25.0023.0016.0014.0019.0019.0013.009.008.005.006.005.004.002.00
Shareholder's Equity-20.0%13516920022483.001091311501651791912020.005.00
  Retained Earnings-15.7%-287-248-213-185-160-131-106-83.40-66.10-49.74-35.03-22.43-14.00-8.18
  Additional Paid-In Capital1.2%42341841441024424023723423122922622414.0013.00
Shares Outstanding0.1%36.0036.0036.0035.0030.0030.0029.0029.0029.0024.0029.0025.0012.00-
Float----597---256---236--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-40.3%-32,030-22,837-23,899-25,812-24,044-20,201-16,795-15,427-9,994-15,899-8,988-6,476-4,075-2,736-1,102-369-252-
  Share Based Compensation30.0%5,0223,8643,5983,4363,2332,7162,7312,5592,3301,9311,9211,463919-----
Cashflow From Investing-337.5%-35.00-8.00-39.00-417-1,756-7012257,37520,4424,550-75.00680-38,510-----
Cashflow From Financing-81.4%116622138162,83720149040031831.00246-152,942-3.0056,388-9,52850.00-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BMEA Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 33,776$ 24,395
General and administrative7,2835,636
Total operating expenses41,05930,031
Loss from operations(41,059)(30,031)
Interest and other income, net1,998980
Net loss(39,061)(29,051)
Other comprehensive loss:  
Unrealized gain (loss) on investments, net 1
Comprehensive loss$ (39,061)$ (29,050)
Net loss per common share, basic$ (1.09)$ (0.98)
Net loss per common share, diluted$ (1.09)$ (0.98)
Weighted-average number of common shares used to compute basic net loss per common share35,890,37029,586,468
Weighted-average number of common shares used to compute diluted net loss per common share35,890,37029,586,468

BMEA Balance Sheet

2024-03-31
Condensed Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 144,918$ 176,866
Prepaid expenses and other current assets2,6482,315
Total current assets147,566179,181
Property and equipment, net4,8065,159
Operating lease right-of-use assets9,0139,714
Restricted cash369370
Other assets6,7405,503
Total assets168,494199,927
Current liabilities:  
Accounts payable4,7096,851
Accrued expenses and other current liabilities17,37913,543
Operating lease liabilities, current3,1662,466
Total current liabilities25,25422,860
Operating lease liabilities, non-current7,9267,830
Total liabilities33,18030,690
Commitments and contingencies (Note 8)
Stockholders' equity  
Preferred stock, $0.0001 par value; 10,000,000 authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31,2024 and December 31, 2023
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 35,933,586 and 35,866,610 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively44
Additional paid-in capital423,196418,058
Accumulated deficit(287,886)(248,825)
Total stockholders' equity135,314169,237
Total liabilities and stockholders' equity$ 168,494$ 199,927
BMEA
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
 CEO
 WEBSITEhttps://biomeafusion.com
 INDUSTRYBiotechnology
 EMPLOYEES94

Biomea Fusion, Inc. Frequently Asked Questions


What is the ticker symbol for Biomea Fusion, Inc.? What does BMEA stand for in stocks?

BMEA is the stock ticker symbol of Biomea Fusion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biomea Fusion, Inc. (BMEA)?

As of Wed May 22 2024, market cap of Biomea Fusion, Inc. is 413.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMEA stock?

You can check BMEA's fair value in chart for subscribers.

What is the fair value of BMEA stock?

You can check BMEA's fair value in chart for subscribers. The fair value of Biomea Fusion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biomea Fusion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BMEA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biomea Fusion, Inc. a good stock to buy?

The fair value guage provides a quick view whether BMEA is over valued or under valued. Whether Biomea Fusion, Inc. is cheap or expensive depends on the assumptions which impact Biomea Fusion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMEA.

What is Biomea Fusion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, BMEA's PE ratio (Price to Earnings) is -3.25 and Price to Sales (PS) ratio is 41.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMEA PE ratio will change depending on the future growth rate expectations of investors.